A Derivative of Plumbagin Targets the JAK2/STAT3 Pathway to Inhibit the Progression of Oral Squamous Cell Carcinoma
Open Access
Abstract
Signal transducer and activator of transcription 3 (STAT3) drives multiple hallmarks of tumorigenesis, making it a validated therapeutic target for diverse cancers. The 1,4-naphthoquinones, such as plumbagin (PL), exhibit anticancer activity via inhibiting STAT3 phosphorylation and dimerization, but their severe cytotoxicity precludes clinical translation. Here, we screened 23 PL derivatives for STAT3 inhibitory activity and normal cell cytotoxicity, identifying III-1a as the optimal candidate with superior STAT3 inhibition and reduced toxicity compared to PL. Molecular docking and cellular thermal shift assay (CTESA) revealed that III-1a binds to the L244 residue within the coiled-coil domain (CCD) of STAT3. In vitro, III-1a dose-dependently suppressed JAK/STAT3 signaling in oral squamous cell carcinoma (OSCC), particularly STAT3 Ser727 phosphorylation. It inhibited STAT3-mediated epithelial—mesenchymal transition (EMT) and induced ferroptosis, thereby attenuating OSCC proliferation, invasion and migration. STAT3 knockdown abrogated its anti-tumor effects, and in vivo studies further confirmed its efficacy against OSCC growth. Collectively, this study identifies a novel PL-derived STAT3 inhibitor targeting STAT3 CCD to regulate EMT and ferroptosis, providing a promising therapeutic candidate for OSCC.Keywords
Funding Information
- National Natural Science Foundation of China (82203779)
- National Natural Science Foundation of China (82201996)
This publication has 37 references indexed in Scilit:
- Flavokawain A suppresses the vasculogenic mimicry of HCC by inhibiting CXCL12 mediated EMTPhytomedicine, 2023
- Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancerRedox Biology, 2022
- Molecular biological mechanism of action in cancer therapies: Juglone and its derivatives, the future of developmentBiomedicine & Pharmacotherapy, 2022
- Design, synthesis and biological evaluation of novel plumbagin derivatives as potent antitumor agents with STAT3 inhibitionBioorganic Chemistry, 2020
- Transferrin‐bearing liposomes entrapping plumbagin for targeted cancer therapyJournal of Interdisciplinary Nanomedicine, 2019
- Emerging role of plumbagin: Cytotoxic potential and pharmaceutical relevance towards cancer therapyFood and Chemical Toxicology, 2019
- Plumbagin suppresses the human large cell lung cancer cell lines by inhibiting IL-6/STAT3 signaling in vitroInternational Immunopharmacology, 2018
- Sophoraflavanone G induces apoptosis of human cancer cells by targeting upstream signals of STATsBiochemical Pharmacology, 2013
- Anticancer activity and SAR studies of substituted 1,4-naphthoquinonesBioorganic & Medicinal Chemistry, 2013
- STAT3 activation induced by Epstein-Barr virus latent membrane protein1 causes vascular endothelial growth factor expression and cellular invasiveness via JAK3 And ERK signalingEuropean Journal of Cancer, 2010